HICKSVILLE, NY / ACCESSWIRE / October 19, 2017 / Canbiola, Inc. CANB, in it's continuing effort to partner with the top people in the global health and wellness field, announced today that the company has added Dr. John P. Salerno to its Medical Advisory Board. Dr. Salerno was also signed as a distributor for Canbiola products. Dr. Salerno will utilize and distribute Canbiola products through his network of clinics globally, including the US, Japan, and Brazil. As a pioneer in the International practice of complementary medicine, Dr. Salerno will help guide the Company in the development of new and innovative products and delivery systems. Dr. Salerno stated,"I am very excited to join the Canbiola team in selling the finest and purest form of Hemp derived CBD. This can be a game-changer in treating my patients with potentially many medical applications."
Marco Alfonsi, Canbiola CEO, stated, "We are continuing to execute our plan to strengthen not only our Medical Advisory Board but also our distribution network. With the addition of Dr. Salerno, we have added our ability to reach a global market for our products. The company has already seen the benefits of this strategy with better than expected results from previously added medical advisors, and I have no doubt that this last addition will further grow both sales and geographically expand our client base."
About Dr. John P. Salerno
Dr. John P. Salerno is an international pioneer in the practice of complementary medicine. Among many other accomplishments, he is well-known for his vitamin IV suites, weight-loss treatments, and chelation therapy, a therapy that removes heavy metals from the body.
The Salerno Center for Complementary Medicine in New York City combines the wisdom of alternative healing with the teachings of traditional medicine, helping patients to live healthier and happier lives.
After the terrorist bombings of September 11, 2001, Dr. Salerno served as the Medical Director for the World Trade Center Landfill, a position that earned him a commendation from the then-mayor, Rudy Giuliani.
Furthermore, he was charged with monitoring the health of public workers assigned to manage the massive landfill, as much of the debris from the World Trade Center was riddled with airborne chemicals, heavy metals, and toxic buildup.
Dr. Salerno has founded and guides many medical clinics internationally, including seven in Tokyo, two in Brazil, and two in the US. In addition, he personally trains physicians worldwide. He has served as a clinical preceptor at the Yale University School of Medicine, as well as the Medical Director of St. Vincent's Immediate Health Care in Shelton, Connecticut.
Dr. Salerno is a much sought-after expert in the field of health and wellness. He has been interviewed by many media outlets, including local news, Fox Business, and Telemundo, among others.
About Canbiola, Inc.
Canbiola, Inc. is a public company trading under symbol CANB. The company's focus is in the sale of a variety of Cannabidiol (CBD) based products derived from legally imported Hemp. Canbiola is in the process of developing its own line of proprietary products, as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. The company has already launched several products found at www.canbiola.com. Cannabis is currently federally illegal and has been legalized for medical purposes in varying forms in only a limited number of states.
The company also owns two technological solutions, "WRAPmail" (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, and "Prosperity Systems" and the "Bullseye" platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance.
Forward-Looking Statements and Risks and Uncertainties:
Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected results, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. We do not undertake to update any statement should actual result differ from the forward-looking statement.
For complete information regarding our business at Canbiola:
Canbiola Investor Relations
IR@canbiola.com
Phone 516-544-8219
http://www.canbiola.com
SOURCE: Canbiola Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
